Skip to main
PSNL
PSNL logo

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 70%
Buy 10%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc. demonstrated significant financial growth in 2024, with biopharma testing and services revenue surging by 59% to $51 million, compared to $32 million in 2023, indicating strong demand for its genomic solutions. Additionally, the company's gross margin improved by 50 basis points year-over-year to reach 27.1% in 4Q24, surpassing the consensus forecast, driven by a favorable customer mix and increased biopharma volume. The company is strategically increasing its cash burn to enhance commercial capabilities in anticipation of potential reimbursement for its NeXT Personal product in the second half of 2025, further signifying its commitment to growth and market expansion.

Bears say

Personalis Inc. reported a 15% decline in 4Q24 revenue, amounting to $16.8 million, which was below market consensus, indicating continuing financial struggles. The company's reliance on the ImmunoID NeXT platform raises concerns about future revenue sustainability, particularly with anticipated slower growth in biopharma revenues and diminished contributions from key clients like Natera. Additionally, significant risks such as reduced customer adoption of new offerings and intensified competition further exacerbate the negative outlook for Personalis's stock, suggesting challenges in achieving projected growth targets.

Personalis Inc (PSNL) has been analyzed by 10 analysts, with a consensus rating of Buy. 70% of analysts recommend a Strong Buy, 10% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 10 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.